Citations

Showing 10 of 108083 citations.

Racial and ethnic disparities in emergency department–initiated buprenorphine across five health care systems
Holland, Wesley C., Jeffery, Molly M. , Stevens, Maria , Melnick, Edward R. , Dziura, James , Khidir, Hazar , Skains, Rachel M. , D’Onofrio, Gail , Soares, William E. , Jeffery, Molly Moore , Melnick, Edward R , Skains, Rachel M , Soares, William E , Li, Fangyong , Nath, Bidisha

Mayo Clinic

Academic Emergency Medicine | January 20, 2023 | Volume: 30 | Issue: 7 | Pages: 709-720

10.1111/acem.14668 | PMID 36660800 Get It

AbstractBackgroundOpioid overdose deaths have disproportionately impacted Black and Hispanic populations, in part due to disparities in treatment access. Emergency departments (EDs) serve as a resource for patients with opioid use disorder (OUD), many of whom have difficulty accessing outpatient addiction programs. However, inequities in ED treatment for OUD remain poorly understood.MethodsThis secondary analysis examined racial and ethnic differences in buprenorphine access using data from EMBED, a study of 21 EDs across five health care systems evaluating a clinical decision support system for initiating ED buprenorphine. The primary outcome was receipt of buprenorphine, ED administered or prescribed. Hospital type (academic vs. community) was evaluated as an effect modifier. Hierarchical models with cluster effects for site and clinician were used to assess buprenorphine receipt by race and ethnicity.ResultsBlack patients were less likely to receive buprenorphine (6.4% [51/801] vs. White patients 8.5% [268/3154], odds ratio [OR] 0.59, 95% confidence interval [CI] 0.45–0.78). This association persisted after adjusting for age, insurance, gender, clinician X‐waiver, hospital type, and urbanicity (adjusted OR [aOR] 0.64, 95% CI 0.48–0.84) but not when discharge diagnosis was included (aOR 0.75, 95% CI 0.56–1.02). Hispanic patients were more likely to receive buprenorphine (14.8% [122/822] vs. non‐Hispanic patients, 11.6% [475/4098]) in unadjusted (OR 1.57, 95% CI 1.09–1.83) and adjusted models (aOR 1.41, 95% CI 1.08–1.83) but not including discharge diagnosis (aOR 1.32, 95% CI 0.99–1.77). Odds of buprenorphine were similar in academic and community EDs by race (interaction p = 0.97) and ethnicity (interaction p = 0.64).ConclusionsBlack patients with OUD were less likely to receive buprenorphine whereas Hispanic patients were more likely to receive buprenorphine in academic and community EDs. Differences were attenuated with discharge diagnosis, as fewer Black and non‐Hispanic patients were diagnosed with opioid withdrawal. Barriers to medication treatment are heterogenous among patients with OUD; research must continue to address the multiple drivers of health inequities at the patient, clinician, and community level.
Targeted Atrial Fibrillation Therapy and Risk Stratification Using Atrial Alternans
Muthavarapu, Neha, Manga, Sharanya, Bhanushali, Aditi Kishor , Yadav, Ashima , Damani, Devanshi N. , Arunachalam, Shivaram P. , Kulkarni, Kanchan , Mohan, Anmol, Sharma, Palak, Damani, Devanshi Narendra, Arunachalam, S P , Kulkarni, Kanchan , Mohan, Anmol , Sharma, Palak , Bhanushali, Aditi , Yadav, Ashima, Jaı̈s, Pierre , Walton, Richard D.

Mayo Clinic

Journal of Cardiovascular Development and Disease | January 20, 2023 | Volume: 10 | Issue: 2 | Pages: 36

10.3390/jcdd10020036 | PMID 36826532 Get It

Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac alternans are a beat-to-beat oscillation of electrical activity and the force of cardiac muscle contraction. Extensive evidence has demonstrated that microvolt T-wave alternans can predict ventricular fibrillation vulnerability and the risk of sudden cardiac death. The majority of our knowledge of the mechanisms of alternans stems from studies of ventricular electrophysiology, although recent studies offer promising evidence of the potential of atrial alternans in predicting the risk of AF. Exciting preclinical and clinical studies have demonstrated a link between atrial alternans and the onset of atrial tachyarrhythmias. Here, we provide a comprehensive review of the clinical utility of atrial alternans in identifying the risk and guiding treatment of AF.
Inhibition of Neutral Sphingomyelinase 2 by Novel Small Molecule Inhibitors Results in Decreased Release of Extracellular Vesicles by Vascular Smooth Muscle Cells and Attenuated Calcification
Pavlic, Angelina , Poelman, Hessel , Wasilewski, Grzegorz, Wichapong, Kanin , Lux, Petra , Maassen, Cecile , Schurgers, Leon J. , Reutelingsperger, Chris , Nicolaes, Gerry A. F. , Schurgers, Leon , Reutelingsperger, Chris P , Nicolaes, Gerry A F , Wichapong, Kanin , Lutgens, Esther

Mayo Clinic

International Journal of Molecular Sciences | January 20, 2023 | Volume: 24 | Issue: 3 | Pages: 2027

10.3390/ijms24032027 | PMID 36768348 Get It

Vascular calcification (VC) is an important contributor and prognostic factor in the pathogenesis of cardiovascular diseases. VC is an active process mediated by the release of extracellular vesicles by vascular smooth muscle cells (VSMCs), and the enzyme neutral sphingomyelinase 2 (nSMase2 or SMPD3) plays a key role. Upon activation, the enzyme catalyzes the hydrolysis of sphingomyelin, thereby generating ceramide and phosphocholine. This conversion mediates the release of exosomes, a type of extracellular vesicles (EVs), which ultimately forms the nidus for VC. nSMase2 therefore represents a drug target, the inhibition of which is thought to prevent or halt VC progression. In search of novel druglike small molecule inhibitors of nSMase2, we have used virtual ligand screening to identify potential ligands. From an in-silico collection of 48,6844 small druglike molecules, we selected 996 compounds after application of an in-house multi-step procedure combining different filtering and docking procedures. Selected compounds were functionally tested in vitro; from this, we identified 52 individual hit molecules that inhibited nSMase2 activity by more than 20% at a concentration of 150 µM. Further analysis showed that five compounds presented with IC50s lower than 2 µM. Of these, compounds ID 5728450 and ID 4011505 decreased human primary VSMC EV release and calcification in vitro. The hit molecules identified here represent new classes of nSMase2 inhibitors that may be developed into lead molecules for the therapeutic or prophylactic treatment of VC.
Safety of endoscopic ultrasound-guided tissue acquisition with uninterrupted direct oral anticoagulation in a swine model
Paredes, Ana García García de , Hartley, Christopher , Hernández-Lara, Ariosto H. , Pruthi, Rajiv K. , Gleeson, Ferga C. , Levy, Michael J. , Rajan, Elizabeth , Garcia Garcia de Paredes, Ana , AbiMansour, Jad P. , Valls, Eric J. Vargas, Hartley, Christopher P , Vargas, Eric J. , Graham, Rondell P. , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | January 19, 2023 | Volume: 11 | Issue: 04 | Pages: E413-E418

10.1055/a-2016-0160 | PMID 37124710 Get It

Abstract Background and study aims The risk of bleeding with endoscopic ultrasound-guided tissue acquisition (EUS-TA) in patients on uninterrupted antithrombotic agents is unknown. This study aimed to assess the safety of EUS-TA without discontinuing direct oral anticoagulants. Methods Twenty pigs were randomized (1:1) to oral apixaban or placebo. Treatment was administered for 3 days before and 3 days after EUS-TA of the pancreas. Primary endpoint was occurrence of clinically significant bleeding events (CSBEs), defined as a composite outcome of drop in hemoglobin ≥ 2 g/dL and evidence of intraprocedural or post-procedure bleeding. Secondary outcome was cytopathological adequacy of acquired specimens. Endoscopists and pathologists were blinded to the treatment arm. Results Total of 80 tissue samples were obtained. CSBE occurred in one animal with apixaban levels above the upper limit (P = 1). Intraprocedural bleeding occurred in five animals (25 %), four of which from the apixaban group. Hematoma at necropsy was found in 10 animals (50 %), six of which were on apixaban. Median drop in hemoglobin was similar in both groups. Adequacy of specimens for cytology and pathology evaluation was confirmed in 20 of 20 and 19 of 20 animals, respectively. Conclusions In this pilot preclinical trial, EUS-TA under apixaban showed a trend toward higher minor bleeding events but did not increase CSBE or prevent adequate cytopathological evaluation.
The Nephrologist's Role in Supporting People with CKD and Unplanned Pregnancy Post-Dobbs
Kattah, Andrea G. , Butler, Catherine R.

Mayo Clinic

Journal of the American Society of Nephrology | January 19, 2023 | Volume: 34 | Issue: 4 | Pages: 530-532

10.1681/asn.0000000000000081 | PMID 36749205 Get It

Staged Resection of Difficult-to-Treat Intracranial Meningiomas: A Systematic Review of the Indications, Surgical Approaches, and Postoperative Outcomes
Kuo, Cathleen C. , Patel, Neal , Brown, Nolan J. , Pennington, Zach , Bui, Nicholas, Reardon, Taylor , Hsu, Frank P. K. , Mohyeldin, Ahmed, Pennington, Zach , Gendreau, Julian , Lien, Brian V. , Prevedello, Daniel M. , Kuan, Edward C

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | January 19, 2023 | Volume: 85 | Issue: 02 | Pages: 131-144

10.1055/a-2015-8238 | PMID 38449578 Get It

Abstract Introduction Meningiomas—the most common extra-axial tumors—are benign, slow-growing dural-based lesions that can involve multiple cranial fossae and can progress insidiously for years until coming to clinical attention secondary to compression of adjacent neurovascular structures. For complex, multicompartmental lesions, multistaged surgeries have been increasingly shown to enhance maximal safe resection while minimizing adverse sequela. Here, we systematically review the extant literature to highlight the merits of staged resection. Methods PubMed, Scopus, and Web of Science databases were queried to identify articles reporting resections of intracranial meningiomas using a multistaged approach, and articles were screened for possible inclusion in a systematic process performed by two authors. Results Of 118 identified studies, 36 describing 169 patients (mean age 42.6 ± 21.3 years) met inclusion/exclusion criteria. Petroclival lesions comprised 57% of cases, with the most common indications for a multistaged approach being large size, close approximation of critical neurovascular structures, minimization of brain retraction, identification and ligation of deep vessels feeding the tumor, and resection of residual tumor found on postoperative imaging. Most second-stage surgeries occurred within 3 months of the index surgery. Few complications were reported and multistaged resections appeared to be well tolerated overall. Conclusions Current literature suggests multistaged approaches for meningioma resection are well-tolerated. However, there is insufficient comparative evidence to draw definitive conclusions about its advantages over an unstaged approach. There are similarly insufficient data to generate an evidence-based decision-making framework for when a staged approach should be employed. This highlights the need for collaborative efforts among skull base surgeons to establish an evidentiary to support the use of staged approaches and to outline those indications that merit such an approach.
Immunology of Giant Cell Arteritis
Weyand, Cornelia M. , Goronzy, Jörg J. , Goronzy, Jorg

Mayo Clinic

Circulation Research | January 19, 2023 | Volume: 132 | Issue: 2 | Pages: 238-250

10.1161/circresaha.122.322128 | PMID 36656970 Get It

Giant cell arteritis is an autoimmune disease of medium and large arteries, characterized by granulomatous inflammation of the three-layered vessel wall that results in vaso-occlusion, wall dissection, and aneurysm formation. The immunopathogenesis of giant cell arteritis is an accumulative process in which a prolonged asymptomatic period is followed by uncontrolled innate immunity, a breakdown in self-tolerance, the transition of autoimmunity from the periphery into the vessel wall and, eventually, the progressive evolution of vessel wall inflammation. Each of the steps in pathogenesis corresponds to specific immuno-phenotypes that provide mechanistic insights into how the immune system attacks and damages blood vessels. Clinically evident disease begins with inappropriate activation of myeloid cells triggering the release of hepatic acute phase proteins and inducing extravascular manifestations, such as muscle pains and stiffness diagnosed as polymyalgia rheumatica. Loss of self-tolerance in the adaptive immune system is linked to aberrant signaling in the NOTCH pathway, leading to expansion of NOTCH1 + CD4 + T cells and the functional decline of NOTCH4 + T regulatory cells (Checkpoint 1). A defect in the endothelial cell barrier of adventitial vasa vasorum networks marks Checkpoint 2; the invasion of monocytes, macrophages and T cells into the arterial wall. Due to the failure of the immuno-inhibitory PD-1 (programmed cell death protein 1)/PD-L1 (programmed cell death ligand 1) pathway, wall-infiltrating immune cells arrive in a permissive tissues microenvironment, where multiple T cell effector lineages thrive, shift toward high glycolytic activity, and support the development of tissue-damaging macrophages, including multinucleated giant cells (Checkpoint 3). Eventually, the vascular lesions are occupied by self-renewing T cells that provide autonomy to the disease process and limit the therapeutic effectiveness of currently used immunosuppressants. The multi-step process deviating protective to pathogenic immunity offers an array of interception points that provide opportunities for the prevention and therapeutic management of this devastating autoimmune disease.
Effect of rapid colonic transit on stool microbiome and short-chain fatty acids in diarrhoea-predominant irritable bowel syndrome
BouSaba, Joelle, Zheng, Ting , Dilmaghani, Saam , Johnson, Stephen , Camilleri, Michael , Camilleri, M , Zheng, Ting, Chen, Jun

Mayo Clinic

Gut | January 19, 2023 | Volume: 73 | Issue: 2 | Pages: 375-376

10.1136/gutjnl-2022-329359 | PMID 36657960 Get It

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
Sise, Meghan E. , Wang, Qiyu , Moreno, Daiana , Harden, Destiny , Smith, R. Neal , Rosales, Ivy A. , Chute, Sarah, Cornell, Lynn D. , Fadden, Riley, Sullivan, Ryan J. , Yang, Nancy, Barmettler, Sara , Wells, Sophia L., Reynolds, Kerry L. , Farmer, Jocelyn R. , Herrmann, Sandra M , Sullivan, Ryan J , Gupta, Shruti , Reynolds, Kerry L , Cornell, Lynn , Seethapathy, Harish Shanthanu , Colvin, Robert B. , Herrmann, Sandra M. , Gupta, Shruti , Villani, Alexandra–Chloé

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 19, 2023 | Volume: 11 | Issue: 1 | Pages: e006222

10.1136/jitc-2022-006222 | PMID 36657813 Get It

Background Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulationpreviously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aid the diagnosis of ICI-nephritis. Methods A retrospective cohort of patients diagnosed with ICI-nephritis was compared with three prospectively enrolled control cohorts: ICI-treated controls without immune-related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA, IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls. Results sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9–3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5–0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7–1.1, p=0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (area under the curve >96%) when compared with either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+T cells, CD45RA+CD8+ T cells, memory CD27+B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared with ICI-treated controls. Gene expressions for IL2RA , IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared with controls. Conclusion Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis.